You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The research may inform the use of a liquid biopsy assay for tracking SMM progression that improves on bone marrow aspirate analysis and is easier for patients to access.
The European Commission approved Merck's PD-1 inhibitor as a frontline therapy for this patient population based on the results of the Keynote-177 trial.
The SOPHIA trial reported median progression-free survival of 5.8 months for HER2-positive, metastatic breast cancer patients on margetuximab.
A data safety monitoring committee said the trial, exploring the first-line activity of bintrafusp against Keytruda in PD-L1-high, advanced NSCLC, wouldn't meet its primary endpoint.
News items for the week of Jan. 18, 2021.
The researchers will compare saliva and plasma samples from 50 patients with non-small cell lung cancer to identify circulating tumor DNA in saliva.